E
enGene Therapeutics Inc.
ENGNCIK 0001980845NasdaqEmerging GrowthBiological Products, (No Diagnostic Substances)Z4CAFY ends Oct 31
Period
FY 2025
Revenue
—
Net Income
$-117.30M
Total Assets
$221.47M
Equity
$167.71M
Shares Out
66.99M
Op. Cash Flow
$-99.20M
Business
enGene Holdings Inc. is a clinical-stage biotechnology company developing non-viral genetic medicines that deliver therapeutics to mucosal tissues and other organs. Its main products and technologies include the proprietary dually derived chitosan (DDX) gene delivery platform and lead candidate detalimogene voraplasmid, an intravesical gene therapy in the LEGEND Phase 1/2 trial for non‑muscle invasive bladder cancer (NMIBC) with CIS. The company operates R&D, clinical development, manufacturing scale-up and intellectual property management functions. It focuses primarily on the United States market, relying on contract manufacturers and plans for direct U.S. commercialization while selectively partnering internationally.
Summary from filing dated 2025-12-22
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-10-31 | FY 2024 2024-10-31 | FY 2023 2023-10-31 | FY 2022 2022-10-31 |
|---|---|---|---|---|---|
| Research and development | 94 | 38 | 16 | 15 | |
| General and administrative | 29 | 24 | 10 | 4 | |
| Total operating expenses | 123 | 62 | 26 | 19 | |
| Loss from operations | 123 | 62 | 26 | 19 | |
| Interest income | −9 | −10 | −1 | −129,000 | |
| Interest expense | 3 | 3 | 5 | — | |
| Gain on extinguishment of debt | 0 | 366,000 | 3 | — | |
| Other expenses (income), net | 569,000 | 113,000 | 129,000 | 662,000 | |
| Total other income, net | −6 | −7 | 74 | 5 | |
| Net loss before income taxes | 117 | 55 | 100 | 24 | |
| Provision for (recovery of) income taxes | 0 | −19,000 | 17,000 | 22,000 | |
| Net loss | 117 | 55 | 100 | 24 | |
| Unrealized (gain) loss on available-for-sale investments | −531,000 | −403,000 | — | — | |
| Total comprehensive loss | 117 | 55 | 100 | 23 | |
| Net loss per share of common shares, basic | 2.29 | 1.46 | 151.22 | 44.3 | |
| Net loss per share of common shares, diluted | 2.29 | 1.46 | 151.22 | 44.3 | |
| Weighted-average common shares outstanding, basic | 51 | 38 | 692,609 | 655,153 | |
| Weighted-average common shares outstanding, diluted | 51 | 38 | 692,609 | 655,153 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-10-31 | FY 2024 2024-10-31 | FY 2023 2023-10-31 | FY 2022 2022-10-31 | FY 2021 2021-10-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 50 | 173 | 82 | 20 | — | |
| Marketable securities - short term | 144 | 65 | — | — | — | |
| Restricted investments | 79,000 | 72,000 | 76,000 | 74,000 | — | |
| Investment tax credits receivable | 927,000 | 332,000 | 2 | 1 | — | |
| Prepaid and other current assets | 7 | 9 | 2 | 739,000 | — | |
| Total current assets | 201 | 247 | 85 | 23 | — | |
| Marketable securities - long term | 9 | 60 | — | — | — | |
| Property and equipment, net | 2 | 1 | 589,000 | 387,000 | — | |
| Operating lease right of use assets | 8 | 2 | — | — | — | |
| Other assets | 1 | 1 | 930,000 | 939,000 | — | |
| Total assets | 221 | 311 | 87 | 24 | — | |
| Accounts payable | 7 | 1 | 1 | 723,000 | — | |
| Accrued expenses and other current liabilities | 15 | 12 | 4 | 3 | — | |
| Operating lease liabilities, current | 2 | 423,000 | — | — | — | |
| Current portion of note payable | 8 | 699,000 | 562,000 | 1 | — | |
| Total current liabilities | 32 | 15 | 5 | 5 | — | |
| Note payable, net of current portion | 15 | 22 | 9 | 10 | — | |
| Operating lease liabilities, net of current portion | 6 | 1 | — | — | — | |
| Liabilities, Total | 54 | 39 | 14 | 47 | — | |
| Common shares, no par value; unlimited shares authorized, 52,018,658 and 50,976,676 shares issued and outstanding as of October 31, 2025 and October 31, 2024, respectively. | 513 | 510 | 259 | 16 | — | |
| Additional paid-in capital | 27 | 19 | 14 | 8 | — | |
| Accumulated other comprehensive loss | −888,000 | −1 | −1 | −1 | — | |
| Accumulated deficit | −372 | −255 | −200 | −100 | — | |
| Total shareholder's equity | 168 | 273 | 72 | −77 | −53 | |
| Total liabilities and shareholder's equity | 221 | 311 | 87 | 24 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-10-31 | FY 2024 2024-10-31 | FY 2023 2023-10-31 | FY 2022 2022-10-31 |
|---|---|---|---|---|---|
| Net loss | −117 | −55 | −100 | −24 | |
| Non-cash interest expense | 854,000 | 806,000 | 778,000 | 644,000 | |
| Non-cash lease expense | 378,000 | 163,000 | — | −5,000 | |
| Loss on the disposal of property and equipment | — | 22,000 | — | — | |
| Net amortization of premiums (accretion of discounts) on marketable securities | −3 | −232,000 | — | — | |
| Unrealized foreign currency losses (gains) | 3,000 | −6,000 | 489,000 | — | |
| Share-based compensation expense | 10 | 5 | 3 | 116,000 | |
| Depreciation of property and equipment | 509,000 | 323,000 | 175,000 | 238,000 | |
| Investment tax credit receivable | −595,000 | 2 | −1 | 143,000 | |
| Prepaid expenses and other assets | 2 | −8 | −751,000 | −113,000 | |
| Accounts payable | 5 | 474,000 | 373,000 | −197,000 | |
| Accrued expenses and other current liabilities | 3 | 5 | 868,000 | 2 | |
| Lease liabilities | 274,000 | −49,000 | — | — | |
| Net cash used in operating activities | −99 | −48 | −25 | −18 | |
| Purchases of property and equipment | −1 | −925,000 | −318,000 | −153,000 | |
| Purchases of marketable securities | −161 | −125 | — | — | |
| Proceeds from maturities of marketable securities | 137 | — | — | — | |
| Net cash used in investing activities | −25 | −126 | −318,000 | −153,000 | |
| Payment of Reverse Recapitalization and PIPE Financing costs | — | −613,000 | −10 | — | |
| Proceeds from the February 2024 PIPE Financing | — | 260 | 57 | — | |
| Payments of issuance costs associated with the 2024 PIPE Financing | — | −12 | — | — | |
| Proceeds from exercise of common share warrants | — | 6 | — | — | |
| Proceeds from exercise of stock options | 2 | 113,000 | 44,000 | 12,000 | |
| Repayments of term loan principal | −699,000 | −9 | −2 | — | |
| Proceeds from issuance of term loan | — | 23 | — | 11 | |
| Payments of debt issuance costs associated with the term loan | — | −585,000 | — | −391,000 | |
| Net cash provided by financing activities | 2 | 266 | 86 | 28 | |
| Effect of exchange rate changes on cash | 1,000 | 1,000 | 1,000 | −805,000 | |
| Net (decrease) increase in cash and cash equivalents | −123 | 91 | 61 | 9 | |
| Cash paid for interest | 2 | 2 | 1 | 615,000 | |
| Reverse Recapitalization and PIPE financing transaction costs included within accrued expenses | — | 4 | 613,000 | — | |
| Warrant value issued as part of Amended Term Loan | — | 319,000 | — | — | |
| Right of use assets obtained in exchange for lease liabilities | 6 | 2 | — | — | |
| Property and equipment included in accrued expenses and accounts payable | 332,000 | — | 58,000 | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro